Lymphocytosis and ibrutinib treatment of CLL

Abstract

In this issue of Blood, Woyach et al clarify that prolonged lymphocytosis is composed of biologically inert leukemic cells and does not anticipate poor outcome or relapse. Prolonged lymphocytosis may be perceived as a failure of chronic lymphocytic leukemia (CLL) treatment with ibrutinib. © 2014 by The American Society of Hematology.